Verisim Life, Inc.
VeriSIM Life is dedicated to transforming drug discovery and development through innovative AI-driven science. Founded in 2017 by Dr. Jo Varshney, the company aims to eliminate inaccuracy and waste in translating drug candidates to clinical trials by leveraging AI and multidisciplinary methods to predict patient outcomes, thereby accelerating the development of groundbreaking therapies and improving success rates.
Industries
Nr. of Employees
small (1-50)
Verisim Life, Inc.
1 Sansome Street, Suite 1400, San Francisco, CA 94104
Patents
Systems and methods for full body circulation and drug concentration prediction
US-10854326-B2
View Details
Systems and methods for full body circulation and drug concentration prediction
US-10854326-B2
View DetailsProducts
Translational decision-support platform
A platform that integrates mechanistic simulations with machine learning to predict patient-level drug behavior and produce a quantitative translational score to inform discovery and development decisions.
Collaborative AI-assisted molecule design environment
An interactive design environment combining generative algorithms with human-in-the-loop inputs to produce diverse, high-potential candidate structures in real time.
Translational decision-support platform
A platform that integrates mechanistic simulations with machine learning to predict patient-level drug behavior and produce a quantitative translational score to inform discovery and development decisions.
Collaborative AI-assisted molecule design environment
An interactive design environment combining generative algorithms with human-in-the-loop inputs to produce diverse, high-potential candidate structures in real time.
Services
Collaborative engagements that apply integrated mechanistic and machine-learning models to de-risk discovery and accelerate translational decisions across preclinical and clinical stages.
Generation and use of synthetic patient cohorts and imputation methods to enrich datasets, support stratification, and evaluate trial outcomes in silico.
Support for preparing computational evidence and aligning model outputs with regulatory guidance for inclusion in submissions and regulatory interactions.
Collaborative engagements that apply integrated mechanistic and machine-learning models to de-risk discovery and accelerate translational decisions across preclinical and clinical stages.
Generation and use of synthetic patient cohorts and imputation methods to enrich datasets, support stratification, and evaluate trial outcomes in silico.
Support for preparing computational evidence and aligning model outputs with regulatory guidance for inclusion in submissions and regulatory interactions.
Expertise Areas
- AI-enabled preclinical development
- Model-informed drug development (MIDD)
- Mechanistic PK/PD modeling (PBPK, QSP)
- Virtual clinical trial simulation and design
Key Technologies
- Hybrid AI (knowledge-enhanced AI)
- Deep learning / machine learning
- Mechanistic biosimulation (PBPK, QSP)
- Virtual patient simulation
News & Updates
VeriSIM Life was awarded for its BIOiSIM platform, recognized for transforming drug discovery through predictive modeling and translational intelligence.
Dr. Jo Varshney, founder and CEO, recognized for her leadership in AI in the pharmaceutical industry.
VeriSIM Life received the 'Best AI-Driven Drug Development Engine 2025 - USA' award at the GHP Biotechnology & Lifesciences Awards.
Recognition for BIOiSIM platform's ability to transform drug discovery.
Award at the GHP Biotechnology & Lifesciences Awards.
Recognition of Dr. Jo Varshney for leadership in AI.
VeriSIM Life was awarded for its BIOiSIM platform, recognized for transforming drug discovery through predictive modeling and translational intelligence.
Dr. Jo Varshney, founder and CEO, recognized for her leadership in AI in the pharmaceutical industry.
VeriSIM Life received the 'Best AI-Driven Drug Development Engine 2025 - USA' award at the GHP Biotechnology & Lifesciences Awards.
Recognition for BIOiSIM platform's ability to transform drug discovery.
Award at the GHP Biotechnology & Lifesciences Awards.
Recognition of Dr. Jo Varshney for leadership in AI.